

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## ESRP1 RABBIT PAB

Cat.#: S222311

Product Name: Anti-ESRP1 Rabbit Polyclonal Antibody

Synonyms: RBM35A; RMB35A; DFNB109

UNIPROT ID: Q6NXG1 (Gene Accession - NP\_060167)

**Background:** ESPRI is an epithelial cell-type-specific splicing regulator (Warzecha et al., 2009 [PubMed 19285943]). mRNA splicing factor that regulates the formation of epithelial cell-specific isoforms. Specifically regulates the expression of FGFR2-IIIb, an epithelial cell-specific isoform of FGFR2. Also regulates the splicing of CD44, CTNND1, ENAH, 3 transcripts that undergo changes in splicing during the epithelial-to-mesenchymal transition (EMT). Acts by directly binding specific sequences in mRNAs. Binds the GU-rich sequence motifs in the ISE/ISS-3, a cis-element regulatory region present in the mRNA of FGFR2 (PubMed:19285943). Regulates splicing and expression of genes involved in inner ear development, auditory hair cell differentiation, and cell fate specification in the cochlear epithelium (By similarity).

**Immunogen:** Synthetic peptide of human ESRP1

Applications: ELISA, IHC

Recommended Dilutions: IHC: 50-100; ELISA: 5000-10000

Host Species: Rabbit

**Clonality:** Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG

Purification: Antigen affinity purification

Species Reactivity: Human, Mouse, Rat

**Constituents:** PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

**Research Areas:** Epigenetics and Nuclear Signaling

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



Immunohistochemistry analysis of paraffin embedded Human breast cancer tissue using 222311(ESRP1 Antibody) at a dilution of 1/60(Cytoplasm and Nucleus).



In comparision with the IHC on the left, the same paraffin-embedded Human breast cancer tissue is first treated with the synthetic peptide and then with 222311(Anti-ESRP1 Antibody) at dilution 1/60.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010